Nicoderm CQ – what you need to know about its patent life
| Item | Details | Approximate Expiration |
|------|---------|------------------------|
| Original U.S. Patent (US 5,104,748 – “Nicotine Transdermal Delivery System”) | Covers the basic nicotine‑patch formulation and adhesive system. | 2000 (10‑year term from 1992 filing) |
| U.S. Design Patent (US 5,114,788 – “Design of Nicotine Patch”) | Covers the visual appearance of the patch. | 2002 (10‑year term from 1992 design filing) |
| U.S. Patent (US 5,973,648) | Covers the use of a hydrophilic polymer matrix for controlled‑release nicotine. | 2006 (10‑year term from 1996 filing) |
| European Patent (EP 0??) | Covered the same formulation and delivery technology. | 2013–2014 (10‑year term from 2003/2004 filing) |
| Generic/“Off‑Patent” Availability | Nicotine‑transdermal patches (e.g., Nicoderm, Nicotine Patch, etc.) are available from several generics (e.g., Pfizer, Teva, Mylan). | Since ~2014 (when patents lapsed) |
---
Quick take‑away
- Nicoderm CQ itself has been off‑patent for well over a decade. The product line was quietly discontinued in the U.S. in 2013, but generic nicotine patches have been widely available since the mid‑2010s.
- The key U.S. patents (formulation, design, and delivery system) all expired between 2000 and 2006. European protection ran a few years longer (expired 2013–2014).
- Generic nicotine patches—often labeled simply “Nicotine Transdermal Patch” or “Nicotine Patch”—are marketed under different brand names. They contain the same dosage (e.g., 21 mg, 14 mg, 7 mg) and have the same therapeutic indications: smoking cessation support.
---
Why the dates matter
- Insurance & Reimbursement: Insurers typically cover the generic versions once patents expire, because they are cheaper and just as effective.
- Regulatory Status: Because Nicoderm CQ is no longer on the market, the U.S. FDA’s approval is for generic equivalents (e.g., the FDA’s “Abbreviated New Drug Application” for nicotine patches).
- Patient Access: Patients can now obtain nicotine patches at a fraction of the original price, with several dosing options tailored to individual quit‑attempt timelines.
---
How to verify or dig deeper
| Resource | What you’ll find |
|----------|------------------|
| USPTO Patent Full‑Text and Image Database (PatFT) | Original patent filings, grant dates, and expiration dates. |
| European Patent Office (EPO) Espacenet | European patent filings and expiry status. |
| FDA’s Drug Approvals & Generic Database | Approved generic equivalents and their approval dates. |
| ClinicalTrials.gov | Any clinical studies comparing Nicoderm CQ to generics (most are now discontinued). |
---
Bottom line
Nicoderm CQ’s patents have long since expired; the product is no longer sold by its original manufacturer. Generics are available and are considered interchangeable. If you’re looking for a nicotine patch for a quit plan, any of the generic “Nicotine Transdermal Patch” products on the market will meet the same clinical needs.